Cat. No. | Product name | CAS No. |
DCC2840 |
Jnj-40255293
Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease |
1147271-25-7 |
DCC2841 |
Jnj-40264796
Negative control for JNJ-40068782 |
|
DCC2842 |
Jnj-40355003
Novel inhibitor of fatty acid amide hydrolase (FAAH) |
1394894-41-7 |
DCC2843 |
Jnj-40573663
Negaive control for JNJ-42396302 |
|
DCC2844 |
Jnj-40929837
Novel potent, orally active LTA4H inhibitor |
1191044-42-4 |
DCC2845 |
Jnj-42396302
Novel inhibitor of PDE10A |
1298030-18-8 |
DCC2846 |
Jnj-42491293
Novel ago-PAM for the metabotropic glutamate receptor subtype 2 (mGluR2) |
1376334-37-0 |
DCC2847 |
Jnj-49153390
Novel inhibitor of respiratory syncytial virus (RSV), binding the RSV F glycoprotein and inhibiting membrane fusion |
|
DCC2848 |
Jnj-53721590
Negative control for JNJ-54119936 |
|
DCC2849 |
Jnj-61432059
Novel TARP γ-8 Selective AMPAR Negative Modulator |
2035814-50-5 |
DCC2850 |
Jnj-dgat1-a
Selective DGAT1 inhibitor |
1092067-85-0 |
DCC2851 |
Jnj-dgat2-b
Selective DGAT2 inhibitor |
|
DCC2852 |
Jns 1-40
Novel cysteine-reactive covalent ligand, selectively targeting C377 of PPP2R1A to impair breast cancer signaling, proliferation, and in vivo tumor growth |
|
DCC2853 |
Jp1201
Novel SMAC mimetic, sensitizing non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner |
|
DCC2854 |
Jp4-039
Non-toxic radioprotector GS-nitroxide, improving hematopoiesis in long-term bone marrow cultures (LTBMCs) |
1205492-16-5 |
DCC2855 |
Jr-220
Non-toxic anti-relapse agent, acamprosate |
6933-71-7 |
DCC2856 |
Jra-003
Novel selective inhibitor of nuclear translocation of IKKα as the most potent synthetic gibberellin against cancer-derived cell lines, displaying no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC) |
|
DCC2857 |
Jrc-ii-191
Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor |
|
DCC2858 |
Js399-19
Novel specific inhibitor of Fusarium myosin I; Fungicide |
39491-78-6 |
DCC2859 |
Jsf-2019
Novel antitubercular agent, inhibiting InhA and FAS-II pathway |
|
DCC2860 |
Jsf-2513
Novel potent antitubercular agent, inhibiting InhA and FAS-II pathway |
|
DCC2861 |
Jsi287
Novel ERK inhibitor, alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway |